Adenosine A2A receptor hyperexpression in patients with severe sirs after cardiopulmonary bypass

Journal of Investigative Medicine

Volumn 56, Issue 6, 2008, Pages 864-871

  Kerbaul, François ^a   Bénard, Frédéric ^a   Giorgi, Roch ^b   Youlet, ^c   Carrega, Louis ^c   Zouher, Ibrahim ^c   Mercier, Laurence ^c   Gérolami, Victoria ^c   Bénas, Vincent ^a   Blayac, Dorothée ^a   Gariboldi, Vlad ^a   Collart, Frédéric ^a   Guieu, Régis ^a,c,d  

^a TIMONE HOSPITAL   (France)

^b LERTIM   (France)

^c Laboratoire de Biochimie   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

A2A receptors; Adenosine; Cardiopulmonary bypass; Hemodynamics; SIRS

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; MESSENGER RNA; VASOACTIVE AGENT; ADENOSINE; ADENOSINE A2 RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; HEART HEMODYNAMICS; HEART INFARCTION; HEART SURGERY; HUMAN; MALE; MEAN ARTERIAL PRESSURE; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION; GENETICS; MIDDLE AGED;

ADENOSINE; ADULT; AGED; CARDIOPULMONARY BYPASS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, ADENOSINE A2; RNA, MESSENGER; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 53449100989     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181788d02     Document Type: Article

References (45)

1. Laffey JG, Boylan JF, Cheng DCH. The systemic inflammatory response to cardiac surgery. Anesthesiology. 2002;97:215Y252.
2. Kerbaul F, Guidon C, Lejeune PJ, et al. Hyperprocalcitonemia is related to postoperative severe SIRS associated with coronary artery bypass grafting. J Cardiothorac Vasc Anesth. 2002;16:47Y53.
3. Wan S, Leclerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass. Mechanisms involved and possible therapeutic strategies. Chest. 1997;112:676Y692.
4. Menasche' P. The inflammatory response to cardiopulmonary bypass and its impact on postoperative myocardial function. Curr Opin Cardiol. 1995;10:597Y604.
5. Carrel T, Englberger L, Mohacsi P, et al. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg. 2000;15:347Y353.
6. Newholmes EA, Leech AR. Pathways for the degradation of purines and pyrimidine nucleotides. In: Biochemistry for the Medical Sciences., 5th ed, edited by Chichester: John Wiley and Sons, 1992, pp 507Y508.
7. Sollevi A. Cardiovascular effects of adenosine in man: possible clinical implications. Prog Neurobiol. 1986;27: 319Y349.
8. Hack B, Witting PK, Rayner BS, et al. Oxidant stress and damage in post-ischemic mouse hearts; effects of adenosine. Moll Cell Biochem. 2006;287:165Y175.
9. Kerbaul F, Collart F, Giorgi R, et al. Role of endogenous adenosine as a predictive marker of vasoplegia during cardiopulmonary bypass and postoperative severe SIRS. Crit Care Med. 2006;34:640Y645.
10. Martin C, Leone M, Viviand X, et al. High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit Care Med. 2000;28: 3198Y3202.
11. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50:413Y492.
12. Fredholm BB, Arslan G, Halldner L, et al. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol. 2000;362:364Y374.
13. Picano E, Abbracchio MP. Adenosine, the imperfect endogenous anti-ischemic cardio-neuroprotector. Brain Res Bull. 2000;52:75Y82.
14. Baxter GF. Role of adenosine in delayed preconditioning of myocardium. Cardiovasc Res. 2002;55:483Y494.
15. Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology and pharmacology. Am J Cardiol. 1997;79: 2Y10.
16. Ledent C, Vaugeois JM, Schiffmann SN, et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the A2A receptor. Nature. 1997;388:674Y678.
17. Giaime P, Carrega L, Fenouillet E, et al. Relationship between A2A adenosine receptor expression and intradialytic hypotension during hemodialysis. J Investig Med. 2006;54:473Y477.
18. Carrega L, Saadjian A, Mercier L, et al. Increased expression of A2A adenosine receptors in patients with spontaneous and head up tilt test syncope. Heart Rhythm. 2007;4:870Y876.
19. Thomas T, St Lambert JH, Dashwood MR, et al. Localization and action of A2A receptors in regions of the brainstem important in cardiovascular control. Neuroscience. 2000;95:513Y518.
20. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. New Engl J Med. 2000;343:611Y617.
21. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined. Eur Heart J. 2001;21:1502Y1513.
22. Provenchére S, Planteféve G, Hufnagel G, et al. Renal dysfunction after cardiac surgery with normothermic cardiopulmonary bypass: incidence, risk factors, and effect on clinical outcome. Anesth Analg. 2003;96:1258Y1264.
23. Feindt P, Volkmer I, Seyfert U, et al. Activated clotting time, anticoagulation, use of heparin, and thrombin activation during extracorporeal circulation: changes under aprotinin therapy. Thorac Cardiovasc Surg. 1993;41:9Y15.
24. Arkin DB, Saidman LJ, Benumof JL. Hypotension following cardiopulmonary bypass. Anesth Analg. 1977; 56:720Y724.
25. Muckart DJJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med. 1997;25: 1789Y1795.
26. Fagon JY, Chastre A, Novara P, et al. Characterization of intensive care unit patients using a model based on the presence or absence of organ dysfunctions and/or infection: the ODIN model. Intensive Care Med. 1993;19:137Y144.
27. Nashef SAM, Roques F, Michel P, et al. The EuroSCORE study group European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999; 16:9Y13.
28. Saadjan AY, Paganelli F, Gaubert ML, et al. Adenosine plasma concentration in pulmonary hypertension. Cardiovasc Res. 1999;43:228Y236.
29. Guieu R, Paganelli F, Sampieri F, et al. The use of HPLC to evaluate the variations of blood coronary adenosine levels during percutaneous transluminal angioplasty. Clin Chim Acta. 1994;230:404Y409.
30. Guieu R, Peragut JC, Roussel P, et al. Adenosine and neuropathic pain. Pain. 1996;68:1Y5.
31. Varani K, Laghi-Pasini F, Camurri A, et al. Changes of peripheral A2A adenosine receptors in chronic failure and cardiac transplantation. FASEB J. 2003;17:280Y282.
32. Carrega L, Fenouillet E, Giaime P, et al. Influence of hemodialysis and left ventricular failure on peripheral A2A adenosine receptors. Nephrol Dial Transplant. 2007;22: 851Y856.
33. Poucher SM, Keddie JR, Singh P, et al. The in vitro pharmacology of ZM 241385, a potent, non xanthine A2A selective adenosine receptor antagonist. Br J Pharmacol. 1995;115:1096Y1102.
34. Partrick DA, Moore EE, Fullerton DA, et al. Cardiopulmonary bypass renders patients at risk for multiple organ failure via early neutrophil priming and late neutrophil disability. J Surg Res. 1999;86:42Y49.
35. Seghaye MC, Duchateau J, Grabitz RG, et al. Complement activation during cardiopulmonary bypass in infants and children: relation to postoperative multiple system organ failure. J Thorac Cardiovasc Surg. 1993;106: 978Y987.
36. Saadjian A, Levy S, Francheschi F, et al. Role of endogenous adenosine as a modulator of syncope induced during tilt testing. Circulation. 2002;106:569Y574.
37. Von Kugelgen I, Allgaier C, Schobert A, et al. Co-release of noradrenaline and ATP from cultured sympathetic neurons. Neuroscience. 1994;61:199Y202.
38. Pelleg A, Burnstock G. Physiological importance of ATP release from nerve terminals and its degradation to adenosine in humans. Circulation. 1990;82:2269Y2272.
39. Mosqueda-Garcia R, Furlan R, Tank J, et al. The elusive pathophysiology of neurally mediated syncope. Circulation. 2000;102:2898Y2906.
40. Law R, Valli VE, Conlon BA. Therapeutic potential for transcient inhibition of adenosine deaminase in systemic inflammatory response syndrome. Crit Care Med. 2003;31: 1475Y1481.
41. Cronstein BN, Daguma L, Nichols D, et al. The adenosine/ neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation respectively. J Clin Invest. 1990;85: 1150Y1157.
42. Eppell BA, Newell AM, Brown EJ. Adenosine receptors are expressed during differentiation of monocytes to macrophages in vitro: implications for regulation of phagocytosis. J Immunol. 1989;143:4141Y4145.
43. Nemeth ZH, Csoka B, Wilmanski J, et al. Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis. J Immunol. 2006;176:5616Y5626.
44. Conlon BA, Ross JD, Law WR. Advances in understanding adenosine as a plurisystem modulator in sepsis and the systemic inflammatory response syndrome. Front Biosci. 2005;10:2548Y2565.
45. Shryock JC, Snowdy S, Baraldi PG, et al. A2A adenosine receptor reserve for coronary vasodilation. Circulation. 1998;98:711Y718.